Skip Navigation


European Heart Journal Advance Access originally published online on May 4, 2005
European Heart Journal 2005 26(19):1964-1970; doi:10.1093/eurheartj/ehi292
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/19/1964    most recent
ehi292v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Théroux, P.
Right arrow Articles by Granger, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Théroux, P.
Right arrow Articles by Granger, C. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial

Pierre Théroux1,*, Paul W. Armstrong2, Kenneth W. Mahaffey3, Judith S. Hochman4, Kevin J. Malloy5, Scott Rollins6, Jose C. Nicolau7, Joel Lavoie1, The Minh Luong1, Jeb Burchenal8 and Christopher B. Granger3

1Montreal Heart Institute, Montreal, 5000 Belanger E, Montreal, Quebec, Canada H1T 1C8
2University of Alberta, Edmonton, Alberta, Canada
3Duke Clinical Research Institute, Durham, NC, USA
4New York University School of Medicine, New York, NY, USA
5Procter & Gamble Pharmaceuticals, Mason, OH, USA
6Alexion Pharmaceuticals, Inc., Cheshire, CT, USA
7Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil
8South Denver Cardiology Associates, Denver, CO, USA

Received 26 November 2004; revised 7 March 2005; accepted 24 March 2005; online publish-ahead-of-print 4 May 2005.

* Corresponding author: Tel: 514 376 3330 3616; fax: 514 376 1076. E-mail address: pierre.theroux{at}icm-mhi.org

Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without apparent reductions in infarct size. Inflammation is a critical component of ST-elevation myocardial infarction (STEMI); this substudy examines prognostic values of selected markers and treatment effects.

Methods and results C-reactive protein, interleukin-6 (IL-6), and tumour necrosis factor-{alpha} (TNF-{alpha}) serum levels were assessed in 337 patients enrolled in either the placebo or the pexelizumab 24 h infusion group. Higher C-reactive protein and IL-6 levels at baseline, 24 h, and 72 h were strongly associated with increased subsequent death (P<0.002 at baseline and 24 h, P<0.02 at 72 h); and all baseline marker levels with death or cardiogenic shock (P<0.03) within 90 days. C-reactive protein and IL-6 levels were similar at baseline, but significantly lower 24 h later with pexelizumab, when compared with placebo (17.1 vs. 25.5 mg/L, P=0.03 and 51.0 vs. 63.8 pg/mL, P=0.04, respectively). At 72 h, corresponding levels were similar, whereas TNF-{alpha} was slightly higher (P=0.04) in the treated group.

Conclusion Inflammation markers and their serial changes predict death and shock in patients with STEMI undergoing primary angioplasty. Pexelizumab reduced C-reactive protein and IL-6, suggesting treatment benefits mediated through anti-inflammatory effects.

Key Words: Myocardial infarction • Primary angioplasty • Complement inhibition • Pexelizumab • C-reactive protein • Interleukin-6 • Tumour necrosis factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
H. R. Reynolds and J. S. Hochman
Cardiogenic Shock: Current Concepts and Improving Outcomes
Circulation, February 5, 2008; 117(5): 686 - 697.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Lim, J.-P. Collet, S. Moutereau, N. Guigui, L. Mitchell-Heggs, S. Loric, M. Bernard, S. Benhamed, G. Montalescot, J.-L. D. Rande, et al.
Fetuin-A Is an Independent Predictor of Death after ST-Elevation Myocardial Infarction
Clin. Chem., October 1, 2007; 53(10): 1835 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
The TRIUMPH Investigators
Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial
JAMA, April 18, 2007; 297(15): 1657 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
The APEX AMI Investigators
Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial
JAMA, January 3, 2007; 297(1): 43 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Thielmann, G. Marggraf, M. Neuhauser, J. Forkel, U. Herold, M. Kamler, P. Massoudy, and H. Jakob
Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction.
Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 285 - 293.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.